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Background: Case-finding of chronic obstructive pulmonary disease (COPD) using spirometry
may deter people with normal lung function from stopping smoking. The objective of this study
was to observe the percentage of smokers screened with normal lung function that quit
smoking.
Methods: As part of a study on early detection of COPD, 518 smokers were screened with
normal lung function (post-bronchodilator FEV1/FVC  70%). They were invited for a follow-
up measurement after an average of 2.4 years. Non-smoking was validated by carbon monoxide
(<10 ppm), and respiratory health related quality of life was measured with the Clinical COPD
Questionnaire (CCQ).
Results: A total of 255 participants were followed up (49%). The point prevalence rate of non-
smoking at follow-up was 18% (N Z 47), and 9% assuming that all non-respondents were
smokers. This rate was not lower than the expected rate of quitting in the Dutch population
(8e9%) and primary “care as usual” in smokers screened with abnormal lung function
(10%; p > 0.05 for all comparisons). The average decline in post-bronchodilator FEV1 was
26 mL/year, which was unrelated to smoking status at follow-up. Non-smokers showed a
clinically meaningful and statistically significant (p < 0.001) improvement in CCQ respiratory
symptoms (0.96) and total score (0.51).
Conclusions: Our results do not suggest that early detection of airflow limitation to motivate
smoking cessation reduces the rate of quitting in smokers shown to have normal lung function.
Such smokers should be advised to quit smoking on the grounds that they are likely to improve38 82893; fax: þ31 43 36 19344.
imaas.nl (D. Kotz), g.wesseling@mumc.nl (G. Wesseling), p.n.aveyard@bham.ac.uk (P. Aveyard),
.C.P. van Schayck).
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244 D. Kotz et al.their respiratory health in the short term and reduce their risk for smoking related diseases in
the long term.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Screening and case-finding programs using spirometry can
reduce the proportion of undiagnosed chronic obstructive
pulmonary disease (COPD) patients. Such programs are
usually applied in smokers as smoking is the major risk
factor for the development and progression of COPD.
Stopping smoking will reduce disease progression more
effectively than any other intervention in smokers diag-
nosed with COPD. The justification for screening or case-
finding with spirometry to detect COPD is that it could
motivate cessation, but there is insufficient evidence that
this is the case.1,2 In the most recent randomized
controlled trial, we showed that confronting smokers with
previously undetected COPD did not increase long term
smoking cessation rates.3
Programs for early detection of COPD might not only fail
to increase cessation rates in those diagnosed with COPD,
they might even deter smoking cessation in those shown to
have normal lung function. Most middle-aged smokers
reporting respiratory symptoms do not have COPD on
spirometry, but will still be at risk for other smoking related
diseases and indeed at risk of COPD in the future. If
spirometry is interpreted as evidence that smoking does not
affect them it could deter cessation in the majority of those
screened, this would have a net negative impact on public
health even if it motivates those with COPD to stop.4
However, it is equally plausible that smokers with normal
lung function might interpret the result as showing that
smoking related damage has not yet occurred and that
smoking cessation is still worthwhile. Despite several
studies that have been performed on the effect of
abnormal spirometry on smoking cessation, data showing
the effect of normal spirometry on smoking cessation are
very scarce. One recent study showed no differences in 12
months quit rates between smokers who were screened
with impaired lung function versus smokers with unim-
paired lung function.5
Our study on early detection of airflow limitation for
smoking cessation had two parts. In individuals classified
as having COPD, we conducted a smoking cessation trial.3
In the remaining individuals with normal lung function, we
conducted a prospective cohort study of which the results
are presented in this paper. The primary aim was to
observe the proportion of smokers that quit smoking. We
expected that smoking cessation rates were not lower
than the rate of quitting in the Dutch population and the
rate of quitting in smokers who were screened with
abnormal lung function and received primary “care as
usual” for smoking cessation. This would suggest no
counterproductive effect of normal spirometry on smoking
cessation. Secondary aims of this cohort study were to
observe the change in lung function and respiratory health
related quality of life and their relations to smoking
cessation.Methods
The full protocol of our study has been published else-
where.6 In brief, current smokers with 10 or more pack-
years smoking history from Dutch and Belgian Limburg
(the area surrounding Maastricht) who were interested in
quitting were recruited by media advertising and from
primary care practices. Based on telephone screening,
smokers were invited for spirometry if they reported at
least one respiratory symptom (cough, shortness of breath
and/or sputum production) but had no prior diagnosis of
COPD and no spirometry in the preceding 12 months. The
study was approved by the medical ethics committee of
Maastricht University Medical Centre and registered at the
Netherlands Trial Register (ISRCTN 64481813).
Baseline spirometry was performed in 925 participants in
the years 2005 and 2006 (Fig. 1). A total of 296 smokers with
mild to moderate COPD were recruited into the smoking
cessation trial, as were another 69 smokers with normal
lung function.3 The latter group was included into the trial
merely for clinical reasons, and because theses smokers
received an intervention, they were not included into the
cohort study and not further taken into account. Twenty-
one smokers with severe and very severe COPD were
referred to their GP or to a respiratory specialist for further
diagnosis and treatment. Ten smokers could not perform
spirometry and 11 withdrew consent at the time of the
measurement. The remaining 518 smokers with normal lung
function formed the baseline cohort of the current analysis.
All these smokers received brief advice to quit smoking at
the time of spirometry but no further smoking cessation
treatment and were asked consent to be contacted again in
the future. In 2008, they received a postal information
letter with an informed consent form and a follow-up
questionnaire (Fig. 1). Participants who responded and
gave consent were invited for spirometry.
Measurements
Spirometry at follow-up was performed identically to
baseline by trained research nurses under supervision of a
lung physician (GW) and according to international
criteria7,8 using a Vitalograph 2120 (Vitalograph Ltd,
Buckingham, England). Normal lung function was defined as
post-bronchodilator (post-bd.) FEV1/FVC  70%. COPD was
defined as post-bd. FEV1/FVC < 70% in combination with
post-bd. FEV1  80% of predicted value (pred.) indicating
mild COPD, FEV1  50% pred. indicating moderate COPD,
and FEV1 < 50% pred. indicating severe to very severe COPD
according to the GOLD guideline.9
Participants were asked at follow-up whether they had
made one or more attempts to quit smoking since baseline
spirometry (yes/no). Those who confirmed were asked
which aids to cessation they had used during any quit
attempt. Participants were defined as non-smokers if they
Telephonic screening:
N=1,711
Baseline spirometry:
N=925
Information letter,
informed consent,
baseline questionnaire
Not eligible: N=560
(N=162 non of the 3 respiratory symptoms, N=125 prior respiratory 
diagnosis, N=103 current use of anti-depressants, N=49 spirometry 
preceding 12 months, N=121 other)
Lost to screening: N=226
(N=15 spirometry not possible, N=101 withdrawal, N=110 no show)
Included into cohort:
N=518
(normal lung function)
Mean 2.4 years follow-up,
questionnaire,
spirometry:
N=255
Excluded: N=42
(N=21 severe/very severe COPD, N=10 non-valid test, N=11 
withdrawal)
Included into trial and randomised: N=365
(N=296 mild/moderate COPD, N=69 normal lung function)
Lost to follow-up: N=263
Counseling RN 
+ nortriptyline 
N=287
(N=228 mild/moderate 
COPD, N=59 normal lung 
function)
Primary 
“care as usual”
N=68
(mild/moderate COPD)
Primary 
“care as usual”
N=10
(normal lung function)
Figure 1 Study flow chart showing the prospective cohort presented in this paper (grey text box with thickened borders) and the
primary “care as usual” group which was used as comparator 3 in our statistical analyses. RN Z respiratory nurse.
Screening smokers with normal spirometry 245reported not smoking at the time of the follow-up visit and
provided a carbon monoxide (CO) measurement in exhaled
breath of <10 ppm.
Respiratory health related quality of life was measured
at baseline and follow-up with the Clinical COPD Ques-
tionnaire (CCQ).10,11 Other measures at baseline included
age, sex, level of education and the Fagerstro¨m Test for
Nicotine Dependence (FTND).12
Statistical analyses
We compared the quit rate in our cohort with three other
quit rates using Pearson’s chi-square test: (1) the quit rate
from a cohort study of the Dutch general population, (2) the
quit rate from a cohort study of the Dutch working pop-
ulation, and (3) the quit rate among smokers screened with
abnormal lung function and recruited into the primary
“care as usual” control group of our smoking cessation trial
(Fig. 1).3,6 We found these the most suitable comparisons
because other designs to assess the impact of normalspirometry on smoking cessation were considered not
feasible or not ethical as we will discuss later.
For comparison 1, we used data from the International
Tobacco Control (ITC) study.13 The ITC study is a prospec-
tive cohort study of a national representative sample of the
Dutch general population. We used data from smokers who
were included at baseline in 2008 and were followed up in
2009 to estimate the 12 month prevalence of smoking
cessation. For comparison 2, we used data from the Maas-
tricht Cohort Study (MCS).14 The MCS is a prospective cohort
study with a large heterogeneous sample of the Dutch
working population. We used data from smokers who were
included at baseline in 1998 and were followed up in 2000
to estimate the 24-month prevalence of smoking cessation.
With regard to both comparison 1 and 2, we counted non-
respondents as smokers (as in our cohort). For comparison
3, smokers who were randomly allocated to the primary
“care as usual” group of our smoking cessation trial were
referred to their own GP who provided the care he or she
usually provided to patients who want to quit smoking
246 D. Kotz et al.which can involve brief advice and the prescription of
smoking cessation medication. Non-smoking was assessed
12 months after the target quit date and validated with
urine cotinine. Smokers with cotinine levels of 50 ng/mL
or lost to follow-up were counted as smokers.
In order to assess whether differential lost to follow-up
had occurred in our cohort, we compared baseline char-
acteristics of respondents versus non-respondents to
follow-up. We included factors that may be associated with
smoking cessation and lung function15: age, sex, level of
education, cigarettes smoked per day, FTND, lung function,
and CCQ scores.
The percentage of non-smokers was calculated for all
respondents and then stratified by duration of follow-up
(based on quartiles) to test whether the point prevalence
rate of non-smoking was associatedwith length of follow-up.
We compared change scores from baseline to follow-up in
lung function and CCQ using unpaired t-tests. To adjust for
potential confounders, we used multiple linear regression
models to regress each outcome (lung function and CCQ
domains) on smoking status at follow-up (main factor) and on
the factors that were associated with loss to follow-up.
We did not impute missing values in any analysis. To
assess differential non-response, we compared participants
with missing data on lung function and CCQ measurements
with participants with complete data with regard to age,
sex, level of education, post-bd. FEV1% pred., FTND at
baseline and smoking status at follow-up.
Results
Of the 518 smokerswith normal lung function at baseline, 255
responded to the follow-up visit (response rate Z 49%;
Fig. 1). The mean duration of follow-up was 28.5 (SDZ 5.7)
months (interquartile range 24e33 months). The baseline
characteristics of this group compared to the 263 non-
responders are presented in Table 1. Respondentswere older
(mean difference 2.4 years, p Z 0.001), smoked fewer
cigarettes per day at baseline (mean difference 2.2Table 1 Baseline characteristics of responders and non-respon
Responders to follow-up (N Z 2
Years of age at baseline 50.0 (8.3)
Male sex, N (%) 148 (58.0)
Level of education 3.8 (1.7)
Cigarettes smoked per day 21.5 (9.8)
FTND 4.3 (1.3)
FEV1 post-bd. (L) 3.10 (0.71)
FVC post-bd. (L) 3.94 (0.90)
FEV1 post-bd. % predicted 94.74 (11.89)
FEV1/FVC post-bd. 78.74 (4.86)
CCQ
Respiratory symptoms 1.79 (0.91)
Functional state 0.88 (0.82)
Mental state 0.86 (0.92)
Total score 1.22 (0.68)
Figures are presented as mean (SD) unless stated otherwise. FEV1 Z
Post-bd. Z post-bronchodilator. FTND Z Fagerstro¨m Test for Nicotin
a Mean duration of follow-up from baseline Z 2.4 years.cigarettes, p Z 0.012), and were more frequently male
(58.0% vs. 48.5%, pZ 0.029). There was no association with
lung function, level of education, or level of nicotine
addiction.
Smoking cessation and attempts to quit
Of the 255 respondents to follow-up, 47 (18.4%) were
CO-validated non-smokers. Assuming all 263 non-respon-
dents were smokers, that percentage would have been 9.1%
(47/518). There was no significant association between the
percentage of non-smokers and the duration of follow-up
(chi-square test for a linear-by-linear association Z 1.378,
df Z 1, p Z 0.24). In the following we contrast this quit
rate with the three comparators.
A total of 1820 smokers were included in the ITC study
at baseline (comparison 1). Of the 1447 respondents to the
12 month follow-up measurement, 162 were self-reported
non-smokers. Assuming that all 373 non-respondents were
smokers, that percentage would have been 8.9% (162/
1820). A total of 3322 smokers were included in the MCS
at baseline (comparison 2). Of the 1922 respondents to the
24-month follow-up measurement, 274 were self-reported
non-smokers. Assuming that all 1400 non-respondents were
smokers, that percentage would have been 8.2% (273/
3322). In our smoking cessation trial (comparison 3), 68
smokers who were screened with mild to moderate airflow
limitation were randomly allocated to primary “care as
usual” for smoking cessation (Fig. 1). The point prevalence
rate of non-smoking at 12 months after the target quit date
was 10.3% (7/68). None of the three point prevalence rates
of smoking cessation was statistically significantly different
from the point prevalence in our cohort (p Z 0.90,
p Z 0.94, p Z 0.74, respectively).
One hundred seventy-two out of 255 participants (66.7%)
from our cohort had made at least one quit attempt since
the baseline measurement. Assuming all 263 non-respon-
dents had not made a quit attempt, that percentage would
have been 33.2% (172/518). A total of 134 participantsders to follow-up.a
55) Non-responders to follow-up (N Z 263) p
47.6 (8.0) 0.001
126 (48.5) 0.029
4.0 (1.6) 0.331
23.6 (9.8) 0.012
4.5 (1.4) 0.094
3.04 (0.71) 0.339
3.84 (0.90) 0.190
93.20 (11.09) 0.129
79.25 (5.06) 0.247
1.85 (0.97) 0.505
0.95 (0.84) 0.375
0.90 (1.00) 0.692
1.30 (0.77) 0.289
Forced Expiratory Volume in 1 s. FVC Z Forced Vital Capacity.
e Addiction. CCQ Z Clinical COPD Questionnaire.10
Screening smokers with normal spirometry 247(77.9% of 172) had used some form of aid to cessation
during a quit attempt. The most frequently used aids were
nicotine patch (30/134, 22.4%), nicotine gum (23/134,
17.2%), and bupropion (27/134, 20.1%). Less than 10% had
used group or individual behavioural support.
Lung function
The average decline in lung function (in terms of post-bd.
FEV1) from baseline to follow-up was 62 mL (this is about
26 mL a year). There were no statistically significant
differences in lung function decline from baseline to
follow-up in smokers versus non-smokers (Table 2). When
adjusting for age, sex, body height, and baseline number of
cigarettes, there was also no association between smoking
status at follow-up and differences scores in lung function
from baseline to follow-up. These findings remained
unchanged after excluding 48 participants (19%) that had
produced an imperfect spirometry either at baseline or at
follow-up.
At follow-up, 28 out of 255 participants (11.0%) had
developed spirometry defined (FEV1/FVC < 70%) COPD;
13 (5.1%) had mild COPD and 15 (5.9%) had moderate COPD
(7 participants did not produce a post-bd. lung function
measurement). These percentages remained unchanged
when participants with imperfect spirometry were
excluded. Stratified by smoking status at follow-up, the
percentage of smokers with COPD was 11.9% (24/202)
among the smokers and 8.7% (4/46) among the non-
smokers; no statistical difference.
Respiratory health related quality of life
As shown in Table 2, non-smokers had a clinically meaningful
decrease in CCQ respiratory symptoms (0.99, SD Z 1.06)
and CCQ total score (0.60, SD Z 0.79) from baseline to
follow-up, indicating health improvement. There was no
clinicallymeaningful change in respiratory symptoms or total
score for participants that were smoking at follow-up (0.02,
SD Z 0.96; 0.09, SD Z 0.69). The mean difference in
change scores from baseline to follow-up between non-
smokers and smokers was 0.96 (SEZ 0.16) for respiratoryTable 2 Mean differences (SD) from baseline to follow-up in lu
non-smokers.
Smoking status at fol
Non-smoker (N Z 46)
FEV1 post-bd. (L) 0.080 (0.23)
FEV1 post-bd. % predicted 0.211 (6.97)
FVC post-bd. (L) 0.051 (0.33)
FEV1/FVC post-bd. 1.31 (4.40)
CCQ
Respiratory symptoms 0.99 (1.06)
Functional state 0.41 (0.95)
Mental state 0.28 (1.01)
Total score 0.60 (0.79)
Figures are presented as mean (SD) unless stated otherwise. FEV1 Z
Post-bd. Z post-bronchodilator. CCQ Z Clinical COPD Questionnairesymptoms and 0.51 (SEZ 0.12) for the total score. These
differences were statistically significant at p < 0.001 and
unchanged on adjustment for age, sex, and baseline number
of cigarettes at 0.99 (SE Z 0.16) and 0.53 (SE Z 0.12),
respectively.
One hundred and nine participants (45.2%) showed
a clinically meaningful improvement in CCQ respiratory
symptoms (i.e., 0.4 points or lower) at follow-up, 71
(27.8%) showed no change, and 61 (23.9%) showed a wors-
ening in symptoms (i.e., 0.4 points or higher). A change
score could not be calculated for the remaining 14 partic-
ipants with missing data. Stratified by smoking status at
follow-up, the percentage of participants that had
improved was 71.7% (33/46) among the non-smokers and
39.0% (76/195) among the smokers, and the percentage
that had deteriorated was 6.6% (4/46) among the non-
smokers and 29.2% (57/195) among the smokers
(p < 0.001). The odds of showing an improvement in CCQ
respiratory symptoms compared to no change or a deterio-
ration in symptoms was more than 4 times higher in non-
smokers than in smokers: OR Z 4.35 (95%CI Z 2.02, 9.35).
Discussion
On the most conservative estimate, 9% of smokers who
had normal lung function at spirometry 2.4 years earlier
had quit smoking by follow-up. The mean decline in lung
function was similar in smokers and non-smokers but people
who had stopped smoking showed a clinically meaningful
and statistically significant improvement in mean CCQ
respiratory symptom (0.96) and total score (0.51).
A randomized controlled trial would be the best method
for analyzing the effect of case-finding with spirometry on
smoking cessation in smokers with normal lung function.
However, that was not feasible; it is impossible to have
a control group of people who were screened but not told
their spirometry and hence not told it was normal because
of ethical reasons and because the controls must assume
their spirometry was not too bad because they were not
told the result. Therefore, we had to use alternative
comparators. Data from the two cohort studies showed that
about 8e9% of smokers from the Dutch population achieveng function and respiratory symptoms between smokers and
low-up p
Smoker (N Z 201)
0.058 (0.21) 0.532
0.070 (6.45) 0.895
0.039 (0.42) 0.859
1.18 (4.77) 0.869
0.02 (0.96) <0.001
0.14 (0.82) 0.057
0.09 (1.06) 0.267
0.09 (0.69) <0.001
Forced Expiratory Volume in 1 s. FVC Z Forced Vital Capacity.
.10
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trial showed that among smokers screened with abnormal
lung function and then referred to their GP for primary
“care as usual”, 10% achieve cessation after one year. The
rate of cessation achieved in our cohort (9%) suggests that
normal spirometry did not deter cessation. This finding
would be in line with the results from a recent study by
McClure et al.5 In that study, smokers received spirometry
with brief face-to-face smoking cessation counselling at
baseline and subsequent free access to a telephone coun-
selling program. The abstinence rates from smoking were
higher in smokers with impaired lung function than in
smokers with normal lung function at 6 months but there
was no statistically significant difference at 12 months.
There was no comparison with smokers with normal lung
function that did not receive spirometry. However, it seems
that a potential negative impact of normal lung function on
smoking cessation is short-lived and not likely to be sus-
tained in the long term.
We found no association between smoking cessation
and change in FEV1. The Lung Health Study showed that
sustained quitters had a lower decline in lung function
(27 mL/year) than continuous smokers (60 mL/year) and
intermittent quitters (48 mL/year), and differences in lung
function were already visible after one year follow-up.16
There are several possible explanations for the differ-
ences between the two studies. The Lung Health Study
involved participants with signs of early COPD whereas
participants in our study did not have COPD at baseline.
Some smokers’ lung function is unaffected by smoking17 and
would not therefore benefit from cessation. Obviously,
smokers without evidence of airflow limitation at around
50 years of age are not very susceptible smokers and not
likely to develop airflow limitation in the short term. The
selection into this study of smokers without COPD and into
the Lung Health Study of smokers with COPD will tend to
lead to these differences in the effects of smoking cessa-
tion on lung function. A further issue is that we did not have
information about the duration of abstinence. Including
recent non-smokers in the group of non-smokers would
reduce the apparent improvements in lung function from
smoking cessation. Finally, the sample was small, reducing
the precision, meaning that a small benefit of cessation on
lung function could have been missed. However, the 95%CI
for the difference between smokers and non-smokers was
from a 94 mL worsening in lung function to a 51 mL
improvement in non-smokers over smokers over two years.
This implies that the degree of improvement in lung func-
tion from abstinence seen in the Lung Health Study was
unlikely to have been missed because of imprecision in this
study.
Several previous longitudinal studies have shown that
respiratory symptoms including cough, phlegm, and wheeze
decrease shortly after smoking cessation.18 For example,
data from the Hordaland County Study, an 11-year
community cohort, showed a 2- to 6-fold higher likelihood
of remission of wheezing and cough in smokers who became
ex-smokers during the follow-up period compared to
continuous smokers.19
Our study has several limitations. The main weakness is
that half the sample declined follow-up two years after
enrolment. As in the Lung Health Study, non-responderswere more likely to be older and lighter smokers at base-
line.16 In both studies, baseline lung function was unrelated
to response. We adjusted for variables that differentiated
between responders and non-responders, but this did not
influence the results for improvement in symptoms or
change in FEV1. It is to be expected, however, that the non-
responders were more likely to have continued smoking
than were the responders. However, assuming that non-
responders were all smokers, suggests that being told lung
function is normal does not weaken the conclusion that
cessation is undermined by normal lung function. It is
unreasonable to assume that all non-responders would not
have tried to stop smoking, but this weakness means that
the true rate of attempting to stop is somewhat uncertain.
When interpreting the results of our study one should
take into account that the impact of spirometry on
smoking cessation may be influenced by the context in
which screening takes place. The impact may be
different if screening is done as part of routine clinical
care for diagnosing COPD than as part of an intervention
designed primarily to show smokers why they should quit
smoking. The design of our study resembles the latter
situation and therefore, our findings do not necessarily
apply to other situations. Furthermore research would be
needed to ascertain the impact of spirometry on smoking
cessation under routine clinical care conditions in which
screening primarily takes place to identify new patients
with COPD.
We conclude that, in the context of a program of early
detection of airflow limitation for smoking cessation, using
spirometry is not likely to have a counterproductive effect
on smoking cessation in smokers screened with normal lung
function. Smokers who are screened with normal lung
function should be advised to quit smoking on the grounds
that they are likely to increase their respiratory health
related quality of life in the short term and reduce their risk
for smoking related diseases in the long term.Acknowledgements
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